Why Victoza Causes Constipation and How to Relieve It

Constipation is a well-documented side effect of Victoza (liraglutide), and it stems from the drug’s fundamental mechanism of action: slowing down the movement of food and waste through your digestive tract. Gut-related side effects affect a majority of people taking GLP-1 receptor agonists like Victoza, though constipation tends to be less frequently reported than nausea or diarrhea. The good news is that for most people it is manageable, and understanding why it happens makes it easier to address.

How Common Are Gut Side Effects on Victoza

Victoza belongs to a class of drugs called GLP-1 receptor agonists, which includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Across clinical trials of these medications, somewhere between 65% and 84% of patients report at least one gastrointestinal side effect.¹ Nausea and diarrhea tend to top the list, but constipation is a frequent complaint as well. The prescribing information for Victoza lists constipation among its common gastrointestinal adverse events, and it tends to appear early in treatment or after dose increases.

Those numbers can sound alarming, but context matters. “Gastrointestinal side effect” covers everything from mild queasiness to significant discomfort, and the majority of cases fall on the milder end. Many people find that symptoms, constipation included, ease up over weeks as the body adjusts. That said, a meaningful minority of patients find the gut effects bothersome enough to consider stopping treatment, which is why strategies for managing them are worth understanding from the start.

Why Victoza Slows Your Bowels

Victoza mimics a natural hormone called GLP-1, which your gut releases after you eat. One of GLP-1’s jobs is to slow gastric emptying so nutrients are absorbed more gradually, helping control blood sugar spikes. But GLP-1 receptors are not just in the stomach. They sit on neurons throughout the enteric nervous system, the network of nerves that controls the entire digestive tract. When Victoza activates those receptors, it dampens the muscle contractions that push waste through the intestines.

Research on gut tissue has shown how this works at a cellular level. GLP-1 reduces the cholinergic contractions of intestinal circular smooth muscle, and it does so by triggering the release of nitric oxide, a chemical that relaxes smooth muscle. In the colon specifically, about 79% of the neurons carrying GLP-1 receptors also produce nitric oxide, which means the colon is particularly responsive to this relaxation signal.² The result is that the wave-like contractions pushing stool toward the exit become weaker and less frequent.

On top of that, Victoza reduces how much you eat. Less food moving through the system means less bulk in the colon, and bulk is one of the main signals that triggers the urge to go. Combine reduced motility with reduced food volume, and you have a recipe for harder, less frequent stools. The delayed gastric emptying that helps with blood sugar and appetite control is essentially the same process that, downstream, leads to constipation.

An Interesting Wrinkle in Diabetic Neuropathy

The relationship between Victoza and gut motility is not entirely straightforward. In people with type 1 diabetes and polyneuropathy, a condition where nerve damage already slows the gut, a randomized trial found that liraglutide actually sped up colonic transit. Large bowel transit time dropped by about 32% compared to placebo in that population.³ The researchers found no significant difference in gastric emptying or small bowel transit between the two groups, suggesting that liraglutide’s effects on the colon specifically might vary depending on the baseline state of someone’s nervous system.

This finding is worth keeping in mind because it shows that “Victoza slows the gut” is not a universal truth for every patient. If your enteric nerves are already underperforming due to diabetic neuropathy, the drug’s stimulation of GLP-1 receptors on those neurons could, in some circumstances, improve rather than worsen transit. For the general population of Victoza users, though, slowed motility and constipation remain the more typical experience.

How Victoza Stacks Up Against Other GLP-1 Drugs

If you are weighing Victoza against other medications in the same class, constipation rates do vary between drugs. A systematic review and meta-analysis of randomized controlled trials comparing five GLP-1 receptor agonists found that semaglutide carries the highest risk for constipation (and vomiting), while tirzepatide carries the highest risk for nausea and diarrhea.⁴ Liraglutide (Victoza) falls somewhere in the middle of the pack for constipation risk specifically.

Adverse event reports from the FDA’s safety database reinforce this picture. Among the GLP-1 drugs tracked, semaglutide showed a disproportionately high signal for constipation in real-world reporting, alongside signals for nausea, vomiting, and delayed gastric emptying.⁵ That does not mean semaglutide is categorically worse for every patient, because these databases reflect voluntary reporting rather than controlled trials, and semaglutide’s popularity means more reports in general. But the pattern is consistent enough that if constipation is your primary concern, it is reasonable to discuss the relative profiles of different GLP-1 drugs with your prescriber.

Practical Ways to Manage Constipation While on Victoza

The standard clinical recommendation for managing gut side effects on GLP-1 drugs starts before you even reach your full dose: slow titration. Victoza is typically started at a low dose and increased gradually over weeks. Rushing the dose escalation is one of the most common reasons people experience worse side effects than they need to. If constipation hits hard after a dose increase, your doctor may hold you at the current dose longer before stepping up again.⁶

Beyond dose pacing, dietary fiber is one of the more evidence-supported interventions. Clinical trials have found that fiber supplementation improves bowel function and stool consistency in patients experiencing GLP-1 receptor agonist side effects.⁷ This makes physiological sense: because Victoza reduces appetite and food intake, many people simply eat less fiber than they used to, and the colon needs fiber to form soft, bulky stool that is easier to pass. Adding a fiber supplement or consciously choosing high-fiber foods can counteract some of the effect.

Other practical measures that help:

Hydration: Slower transit means the colon has more time to absorb water from stool, leaving it harder and drier. Drinking more water than you might think you need helps counteract this.
Physical activity: Movement stimulates gut motility. Even moderate daily walking can make a noticeable difference for people on GLP-1 drugs.
Over-the-counter options: Osmotic laxatives like polyethylene glycol (MiraLAX) are often recommended when lifestyle measures fall short. Stimulant laxatives are typically a second-line choice and are best used occasionally rather than daily.
Meal timing and composition: Smaller, more frequent meals can be easier to process when the gut is moving slowly. Fatty and very rich meals tend to exacerbate the feeling of fullness and sluggish digestion.

The key point is that constipation on Victoza is rarely something you need to simply endure. Most patients can find a manageable combination of adjustments. If basic measures are not working after several weeks, it is worth checking in with your prescriber rather than assuming this is just how the drug feels.

When Constipation Becomes a Red Flag

For the vast majority of people, constipation on Victoza is uncomfortable but not dangerous. There is, however, a more serious end of the spectrum worth knowing about: intestinal obstruction, where the bowel becomes partially or fully blocked. The research on this risk is genuinely mixed, and it is a topic where researchers have gone back and forth.

One large real-world study comparing GLP-1 receptor agonist users to people taking a different class of diabetes medication found that GLP-1 drugs were associated with a higher rate of intestinal obstruction, roughly 1.9 per 1,000 person-years compared to 1.1 per 1,000 person-years. The risk appeared highest after about a year and a half of use.⁸ That sounds worrying, but a separate nationwide database study found no significant difference in bowel obstruction rates between GLP-1 receptor agonist users and a comparison group over one year.⁹

What should you take from this disagreement? The absolute numbers are small in both studies. Even in the study that found an elevated risk, we are talking about fewer than two events per thousand patients per year. But it is a reason to pay attention to warning signs. If your constipation becomes severe, if you develop significant abdominal pain or bloating, if you stop passing gas entirely, or if you experience vomiting along with constipation, those are symptoms that warrant urgent medical attention. The risk of bowel obstruction is not unique to GLP-1 drugs, but the mechanism that slows gut transit could theoretically contribute, and you should not dismiss those symptoms as just a side effect.

What Happens to Your Gut Bacteria

When Victoza slows your gut, it changes the environment your gut bacteria live in. Slower transit means that the bacteria in your colon have a different schedule for receiving the carbohydrates and fiber they ferment. Over time, this can shift which bacterial populations thrive. One review found that GLP-1 receptor agonists can enrich bacteria like Akkermansia and Bacteroides, which are generally considered metabolically favorable, though some studies noted reduced overall microbial diversity.¹⁰

The practical question is whether these microbiome changes contribute to the constipation you experience, or whether they are just a downstream consequence of it. The honest answer is that researchers cannot fully separate microbiome shifts driven by slower transit from those caused by weight loss, dietary changes, or the medications themselves. A randomized trial that directly measured the effect of liraglutide on fecal microbiome composition found no significant changes in overall bacterial makeup or diversity over six weeks of treatment.¹¹ So the jury is still out on whether Victoza has a meaningful, consistent effect on the microbiome beyond what the change in diet and transit would explain on their own.

What this means for managing constipation is that probiotic supplements are unlikely to be a reliable fix, at least based on current evidence. Fiber supplementation is a better bet, because fiber serves double duty: it bulks up stool to ease constipation and it provides the fermentable substrate that your gut bacteria need to produce short-chain fatty acids, which help maintain a healthy colonic lining. If you are going to intervene on the gut microbiome front, feeding the bacteria you already have seems more supported than trying to introduce new ones through a probiotic capsule.

Constipation Versus Diarrhea on the Same Drug

One of the more confusing aspects of Victoza’s gut side effects is that the same drug can cause constipation in one person and diarrhea in another, or even both in the same person at different points in treatment. This is not contradictory once you understand that the drug affects multiple parts of the digestive tract simultaneously. Delayed gastric emptying can cause nausea and a sensation of fullness, while changes in bile acid metabolism and altered fluid secretion in the small intestine can speed things up further downstream. The net result depends on which effect dominates in your particular gut on any given day.

Early in treatment or right after a dose increase, diarrhea and nausea tend to be more common. Constipation often becomes the longer-term pattern as the body adjusts to the new baseline of slower motility. Some people experience an alternating pattern that can feel unpredictable. If you are in that camp, it helps to know that this is a recognized feature of GLP-1 receptor agonists and not a sign that something unusual is going on. Keeping a brief daily log of symptoms can help you and your doctor identify patterns and decide whether dose adjustment or supportive treatment is warranted.

How Fiber Intake Interacts With the Drug’s Mechanism

The fiber recommendation deserves a bit more unpacking, because Victoza changes the rules for how fiber behaves in your gut. Normally, soluble fiber dissolves in water and forms a gel that slows digestion, while insoluble fiber adds bulk and speeds transit. When Victoza is already slowing transit significantly, loading up on soluble fiber without enough water can actually make constipation worse by creating a thick, slow-moving mass. Insoluble fiber from vegetables, whole grains, and bran is typically more helpful for getting things moving.

The reduced food intake that Victoza causes adds another layer. Many patients eat substantially less on the drug, and with less food comes less fiber unless you actively compensate. A person who drops from 2,000 calories a day to 1,300 might lose a third of their dietary fiber intake without realizing it. This alone could explain a meaningful portion of the constipation people experience, independent of any direct pharmacological effect on the gut. Tracking fiber intake for a week or two can reveal whether you have dropped below the roughly 25 to 30 grams per day that most guidelines recommend.¹²

If your food intake has dropped sharply, a fiber supplement like psyllium husk can bridge the gap without requiring you to eat more volume. Start with a low dose and increase gradually, because adding too much fiber too quickly to an already sluggish gut can cause bloating and gas. Think of it as titrating the fiber the same way you titrate the drug: slowly and with attention to how your body responds.

Does Constipation Mean the Drug Is Working

You may have heard the informal claim that gut side effects are a sign the medication is “doing its job.” There is a kernel of truth here in that the same mechanism responsible for appetite suppression and blood sugar control, the slowing of gastric emptying and activation of GLP-1 receptors throughout the gut, is what causes the digestive side effects. People who experience more pronounced GI symptoms sometimes do report stronger appetite suppression and greater weight loss, though this association is not reliable or consistent enough to use as a gauge.

What is definitely not true is that you need to have constipation or nausea for Victoza to be working. Plenty of people get excellent blood sugar control and meaningful weight loss with minimal GI effects, especially when dose titration is managed carefully. If someone tells you that the side effects are the price of admission, that is an oversimplification. Tolerability varies widely between individuals, and the absence of constipation does not mean the drug is failing to act on your metabolism.

The practical takeaway is that constipation should be addressed rather than endured as proof of efficacy. Treating the symptom does not diminish the drug’s therapeutic benefit. The blood sugar and weight effects come primarily from Victoza’s action on the brain’s appetite centers and on pancreatic insulin secretion, not from how uncomfortable your gut feels. Managing the constipation lets you stay on the medication longer and more consistently, which is what actually matters for outcomes.